GSK to buy liver disease drug from Boston Pharmaceuticals for up to $2 billion
GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion. The deal includes an upfront payment of $1.2 billion and milestone payments. Efimosfermin, targeting steatotic liver disease and MASH, is expected to launch in 2029, with (...)
Site référencé: The Economic Times
The Economic Times
Concurrent Gainers : 4 stocks that gain for 5 days in a row
3/05/2025
F&O Talk| Nifty faces key hurdles at 24,600, Bank Nifty scales new peak with 7% rally. What’s ahead ? Explains Sudeep (...)
3/05/2025
Dalal Street Week Ahead : Traders advised to stay cautious, prefer low-beta stocks as Nifty nears resistance
3/05/2025
SBI Q4 results : Net profit slides 10% YoY to Rs 18,642.59 cr, NII surges 3%
3/05/2025
Kotak Mahindra Bank Q4 results : PAT drops 14% YoY, NII up 4%
3/05/2025
How Warren Buffett made $13 billion while others bled
3/05/2025
